Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29616462 | 0.81 | ALDH1A1 (0.61) | CYP1A2ALDH1A1KDM4EMAPTNPSR1 | |
| SCHEMBL22926629 | 0.81 | ALDH1A1 (0.61) | CYP1A2ALDH1A1KDM4EMAPTNPSR1 | |
| SCHEMBL9184880 | 0.79 | CYP1A2 (0.60) | CYP1A2CASP3ALDH1A1KDM4EMAPT | |
| SCHEMBL28777566 | 0.76 | GRM1 (0.38) | CYP1A2ALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL28158463 | 0.75 | CYP1A2 (0.56) | CYP1A2CASP3ALDH1A1KDM4EMAPT | |
| SCHEMBL398765 | 0.75 | CYP1A2 (0.56) | CYP1A2CASP3ALDH1A1KDM4EMAPT | |
| SCHEMBL12834808 | 0.75 | CYP1A2 (0.50) | CYP1A2CASP3ALDH1A1KDM4EMAPT | |
| SCHEMBL14256476 | 0.75 | CYP1A2 (0.50) | CYP1A2CASP3ALDH1A1KDM4EMAPT | |
| SCHEMBL28306505 | 0.75 | CYP1A2 (0.50) | CYP1A2CASP3ALDH1A1KDM4EMAPT | |
| SCHEMBL30297855 | 0.74 | CYP1A2 (0.46) | CYP1A2CASP3ALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4016663-B1 | ELECTRODE MATERIAL FOR THE PRINTING OF POLYMER BATTERIES | INNOVATIONLAB GMBH (DE) | 2023-10-11 | — | — | EP | disclosed |
| US-20220220115-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-07-14 | — | — | US | disclosed |
| WO-2020233592-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHODS AND USES THEREOF | INVENTISBIO SHANGHAI LTD. (CN) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020227588-A1 | PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2020-11-12 | — | — | WO | disclosed |
| US-20200354404-A1 | PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2020-11-12 | — | — | US | disclosed |
| WO-2020079229-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LIMITED (GB) | 2020-04-23 | — | — | WO | disclosed |
| EP-2797417-B1 | SELECTIVE INHIBITION OF PHOSPHOENOLPYRUVATE CARBOXYLASES OF C4 PLANTS | HEINRICH HEINE UNIV DUESSELDORF (DE) | 2019-07-31 | — | — | EP | disclosed |
| WO-2019074979-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | GIRAFPHARMA, LLC (US) | 2019-04-18 | — | — | WO | disclosed |
| WO-2017075629-A2 | WEE 1 KINASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2017-05-04 | — | — | WO | disclosed |
| US-9120767-B2 | Arylosulfonamides for the treatment of CNS diseases | ADAMED SP. Z.O.O. (PL) | 2015-09-01 | — | — | US | disclosed |
| US-20140336200-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ADAMED SP. Z O.O. (PL) | 2014-11-13 | — | — | US | disclosed |
| US-8822517-B2 | Arylosulfonamides for the treatment of CNS diseases | ADAMED SP. Z O.O. (PL) | 2014-09-02 | — | — | US | disclosed |
| US-20130172365-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ADAMED SP. Z.O.O. (PL) | 2013-07-04 | — | — | US | disclosed |
| US-7919528-B2 | Antibiotic; bactericides | GLAXOSMITHKLINE LLC (US) | 2011-04-05 | — | — | US | disclosed |
| US-7700552-B2 | Macrocyclic inhibitors of hepatitis C virus | MEDIVIR AB (SE) | 2010-04-20 | — | — | US | disclosed |
| US-7507726-B2 | Peptide deformylase inhibitors | SMITHKLINEBEECHAM CORPORATION (US) | 2009-03-24 | — | — | US | disclosed |
| US-20090023758-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | MEDIVIR AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20080167302-A1 | Peptide Deformylase Inhibitors | GLAXOSMITHKLINE LLC | 2008-07-10 | — | — | US | disclosed |
| US-20080058312-A1 | Modulators of hepatocyte growth factor/c-Met activity | ANGION BIOMEDICA CORPORATION (US) | 2008-03-06 | — | — | US | disclosed |
| WO-2007064316-A1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023758-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | CTRC, NOX3, HAVCR2 | CYP1A2 1007/4885CASP3 50/4885ALDH1A1 2532/4885 |
| US-20140336200-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ARSA, PMP22, STS | CYP1A2 242/4885CASP3 3226/4885ALDH1A1 132/4885 |
| US-20220220115-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | CYP1A2 3179/4885CASP3 1441/4885ALDH1A1 2869/4885 |
| US-20130172365-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ARSA, PMP22, STS | CYP1A2 242/4885CASP3 3226/4885ALDH1A1 132/4885 |
| US-20080167302-A1 | Peptide Deformylase Inhibitors | PDF, PEPD, DPEP1 | CYP1A2 4681/4885CASP3 2724/4885ALDH1A1 4302/4885 |
| US-20200354404-A1 | PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF | DNPEP, PEPD, ANPEP | CYP1A2 4534/4885CASP3 1914/4885ALDH1A1 4718/4885 |
| US-20080058312-A1 | Modulators of hepatocyte growth factor/c-Met activity | HGF, MET, HDGF | CYP1A2 2896/4885CASP3 1515/4885ALDH1A1 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.